Top

Published in:

01-02-2017 | Original Article

Quality control of involved field radiotherapy in the HD 13 and HD 14 trials

Report of the radiotherapy panel of the German Hodgkin Study Group (GHSG)

Authors: J. Kriz, C. Baues, R. Engenhart-Cabillic, U. Haverkamp, K. Herfart, P. Lukas, A. Plütschow, H. Schmidberger, S. Staar, M. Fuchs, A. Engert, Prof. Dr. H. T. Eich

Published in: Strahlentherapie und Onkologie | Issue 2/2017

Abstract

Introduction

As part of the foundation of the German Hodgkin Study Group (GHSG) in 1978, a central radiotherapy (RT) reference centre was established to evaluate and to improve the quality of treatment. During the study generations, the quality assurance programs (QAP) were continued and adapted to the demands of each study. The purpose of this article is to demonstrate the results of the fifth study generation and to compare them to the previous findings.

Methods

With the start of the fourth GHSG study generation (HD10–12), a central prospective review of all diagnostic images was established to create an individual treatment plan for each early stage study patient. The quality of involved field RT was retrospectively evaluated by an expert panel of radiation oncologists. In the fifth study generation (HD13–15), the retrospective review of radiotherapy performed was refined and the results were compared with the findings of the fourth generation.

Results

The expert panel analyzed the RT planning and application of 1037 (28 %) patients (HD13 n = 465, HD14 n = 572). Simulation films were available in 85 % of cases and verification films in 87 %. RT was assessed as major violation in 46 % (HD13 = 38 %, HD14 = 52 %), minor violation in 9 % (HD13 = 9 %, HD14 = 9 %) and according to the protocol in 45 % (HD13 = 52 %, HD14 = 38 %).

Conclusion

The value for QAP of RT within the GHSG trials is well known. Still there were several protocol violations. In the future, the QAP program has to be adapted to the requirements of “modern RT” in malignant lymphoma.

Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363:640–652CrossRefPubMed

Eich HT, Diehl V, Gorgen H, Pabst T, Markova J, Debus J et al (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28:4199–4206CrossRefPubMed

Engert A, Schiller P, Josting A et al (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with earlystage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21:3601–3608CrossRefPubMed

Eich HT, Muller RP, Engenhart-Cabillic R et al (2008) Involved-node radiotherapy in early-stage Hodgkin’s lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol 184:406–410CrossRefPubMed

Specht L, Yahalom J, Illidge T et al (2014) Modern radiotherapy for Hodgkin lymphoma – field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 89(4):854–862CrossRefPubMed

Müller RP, Eich HT (2005) The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG). Introduction, continuing work, and results of the radiotherapy reference panel. Strahlenther Onkol 181(9):557–566CrossRefPubMed

Duhmke E, Diehl V, Loeffler M et al (1996) Randomized trial with early-stage Hodgkin’s disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys 36:305–310CrossRefPubMed

Eich HT, Engenhart-Cabillic R, Hansemann K et al (2008) Quality control of involved field radiotherapy in patients with early-favorable (HD10) and early-unfavorable (HD11) Hodgkin’s lymphoma: an analysis of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 71(5):1419–1424CrossRefPubMed

Eich HT, Gossmann A, Engert A et al (2007) A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin’s Lymphoma – analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 69(4):1187–1192CrossRefPubMed

10.

Kriz J, Reinartz G, Dietlein M et al (2015) Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 92(1):46–53CrossRefPubMed

11.

Behringer K, Goergen H, Hitz F et al (2015) Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 385:1418–1427CrossRefPubMed

12.

von Tresckow B, Plütschow A, Fuchs M et al (2012) Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 30(9):907–913CrossRef

13.

Eich HT, Staar S, Gossmann A et al (2004) Centralized radiation oncologic review of cross-sectional imaging of Hodgkin’s disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 58(4):1121–1127CrossRefPubMed

14.

Kriz J, Bangard C, Haverkamp U et al (2012) Quality control of involved-field radiotherapy for patients with early stage Hodgkin’s lymphoma based on a central prospective review. Comparison of the results between two study generations of the German Hodgkin Study Group. Strahlenther Onkol 188(8):660–665CrossRefPubMed

15.

Aleman B, Girinsky T, Maazen R et al (2005) Quality control of involved-field radiotherapy in patients with advanced Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 63(4):1184–1190CrossRefPubMed

16.

Kinzie JJ, Hanks GE, MacLean CJ et al (1983) Patterns of care study: Hodgkin’s disease relapse rates and adequacy of portals. Cancer 52:2223–2226CrossRefPubMed

17.

Hoppe RT, Hanlon AL, Hanks GE et al (1994) Progress in the treatment of Hodgkin’s disease in the United States, 1973 versus 1983. The patterns of care study. Cancer 74(12):3198–3203CrossRefPubMed

18.

Hughes DB, Smith AR, Hoppe R et al (1995) Treatment planning for Hodgkin’s disease: a patterns of care study. Int J Radiat Oncol Biol Phys 33(2):519–524CrossRefPubMed

19.

Raemaekers JM, André MP, Federico M et al (2014) Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32:1188–1194CrossRefPubMed

20.

Radford J, Illidge T, Counsell N et al (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 372:1598–1607CrossRefPubMed

21.

Lohr F, Georg D, Cozzi L et al (2014) Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma: When should they be considered and which questions remain open? Strahlenther Onkol 190(10):868–871CrossRef

22.

Kriz J, Spickermann M, Lehrich P et al (2015) Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin’s lymphoma: comparison of ILROG IS-RT and the GHSG IF-RT. Strahlenther Onkol 191(9):717–725CrossRefPubMed

Title: Quality control of involved field radiotherapy in the HD 13 and HD 14 trials
Report of the radiotherapy panel of the German Hodgkin Study Group (GHSG)
Authors: J. Kriz
C. Baues
R. Engenhart-Cabillic
U. Haverkamp
K. Herfart
P. Lukas
A. Plütschow
H. Schmidberger
S. Staar
M. Fuchs
A. Engert
Prof. Dr. H. T. Eich
Publication date: 01-02-2017
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 2/2017
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-016-1036-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Quality control of involved field radiotherapy in the HD 13 and HD 14 trials

Report of the radiotherapy panel of the German Hodgkin Study Group (GHSG)

Abstract

Introduction

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2017

Vertically transmitted HPV-dependent squamous cell carcinoma of the external auditory canal

Bildgeführte intensitätsmodulierte Strahlentherapie vermindert die gastrointestinalen Spätfolgen nach Radiotherapie des Prostatakarzinoms

Patient’s quality of life after high-dose radiation therapy for thoracic carcinomas

New quality assurance program integrating “modern radiotherapy” within the German Hodgkin Study Group

Inklusion von Oxaliplatin in die multimodale Behandlung des lokal fortgeschrittenen Rektumkarzinoms

Erratum to: Fractionated vs. single-fraction stereotactic radiotherapy in patients with vestibular schwannoma